Last reviewed · How we verify

Active Biotech AB — Portfolio Competitive Intelligence Brief

Active Biotech AB pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bayer · 2 shared drug classes
  2. Air Force Military Medical University, China · 1 shared drug class
  3. Astellas Pharma Inc · 1 shared drug class
  4. Actavis Mid-Atlantic LLC · 1 shared drug class
  5. Beijing Children's Hospital · 1 shared drug class
  6. Biogen · 1 shared drug class
  7. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 shared drug class
  8. ALK-Abelló A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Active Biotech AB:

Cite this brief

Drug Landscape (2026). Active Biotech AB — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/active-biotech-ab. Accessed 2026-05-14.

Related